FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marina Cetkovic-Cvrlje

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Procedures

Genes & Molecular Sequences

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.
Marina Cetkovic-Cvrlje; fatih uckun
Effect of targeted disruption of signal transducer and activator of transcription (Stat)4 and Stat6 genes on the autoimmune diabetes development induced by multiple low doses of streptozotocin.
Marina Cetkovic-Cvrlje; fatih uckun
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marina Cetkovic-Cvrlje (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.
Cellular & molecular immunology 2012;9(4):350-60.
2005: Marina Cetkovic-Cvrlje; fatih uckun
Effect of targeted disruption of signal transducer and activator of transcription (Stat)4 and Stat6 genes on the autoimmune diabetes development induced by multiple low doses of streptozotocin.
Clinical immunology (Orlando, Fla.) 2005;114(3):299-306.
2004: Marina Cetkovic-Cvrlje; fatih uckun
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
British journal of haematology 2004;126(6):821-7.
2004: Marina Cetkovic-Cvrlje; fatih uckun
Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Archivum immunologiae et therapiae experimentalis 2004;52(2):69-82.
2004: Marina Cetkovic-Cvrlje; H E Tibbles
Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.
Current pharmaceutical design 2004;10(15):1767-84.
2003: Marina Cetkovic-Cvrlje; Angela L Dragt; Alexei O Vassilev; Xing-Ping Liu; fatih uckun
Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.
Clinical immunology (Orlando, Fla.) 2003;106(3):213-25.
2003: Marina Cetkovic-Cvrlje; Angela L Dragt; fatih uckun
Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
Arzneimittel-Forschung 2003;53(9):648-54.
2002: Marina Cetkovic-Cvrlje; Bertram A Roers; Dawn Schonhoff; Barbara Waurzyniak; Xing-Ping Liu; fatih uckun
Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor.
Leukemia & lymphoma 2002;43(7):1447-53.
2002: Gustavo Glowacki; Rickmer Braren; Kathrin Firner; Marion Nissen; Maren Kühl; Pedro A Reche; J. Fernando Bazan; Marina Cetkovic-Cvrlje; Edward H Leiter; Friedrich Haag; Friedrich Koch-Nolte
The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse.
Protein science : a publication of the Protein Society 2002;11(7):1657-70.
2002: fatih uckun; Bertram A Roers; Barbara Waurzyniak; Xing-Ping Liu; Marina Cetkovic-Cvrlje
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Blood 2002;99(11):4192-9.
2002: fatih uckun; Yaguo Zheng; Marina Cetkovic-Cvrlje; Alexei O Vassilev; Elizabeth Lisowski; Barbara Waurzyniak; Hao Chen; Randy Carpenter; Chun-Lin Chen
In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1224-33.
2001: Gustavo Glowacki; Rickmer Braren; Marina Cetkovic-Cvrlje; Edward H Leiter; Friedrich Haag; Friedrich Koch-Nolte
Structure, chromosomal localization, and expression of the gene for mouse ecto-mono(ADP-ribosyl)transferase ART5.
Gene 2001;275(2):267-77.
2001: Marina Cetkovic-Cvrlje; Bertram A Roers; Barbara Waurzyniak; Xing-Ping Liu; fatih uckun
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Blood 2001;98(5):1607-13.
1998: MM Bridgett; Marina Cetkovic-Cvrlje; Robert W O'rourke; Y Shi; S Narayanswami; J Lambert; V Ramiya; S Baekkeskov; Edward H Leiter
Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic beta-cells.
Diabetes 1998;47(12):1848-56.
1997: Marina Cetkovic-Cvrlje; I C Gerling; A Muir; Mark A Atkinson; John Elliott; Edward H Leiter
Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta-cell antigens.
Diabetes 1997;46(12):1975-82.
1997: Marina Cetkovic-Cvrlje; S D Yang; Edward H Leiter
Mono(ADP-ribosyl)transferase genes and diabetes in NOD mice. Is there a relationship?
Advances in experimental medicine and biology 1997;419():217-27.
1996: M S Hanson; Marina Cetkovic-Cvrlje; V K Ramiya; M A Atkinson; N K Maclaren; Bhagirath Singh; John Elliott; David V Serreze; Edward H Leiter
Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(3):1279-87.